الفهرس Only 14 pages are availabe for public view
 |  | from | 179 |  |  |
| | | from | 179 | | |
Abstract
Background : Gastric cancer (GC) is a major cause of cancer death worldwide, especially in the developing countries. In Egypt, GC is the 12th most common cancer in both sexes representing 1.6% of the total cancers. It is the 12th leading cause of cancer death representing 2.2% of the total cancer mortality. Amplification of the Her2/neu gene and overexpression of the Her2/neu protein in GC is a golden criterion for target therapy with trastuzumab (Herceptin). Results Twenty three cases (27%) were defined as positive for Her2/neu gene amplification and/or protein overexpression. The levels of Her2/neu positive (3+), Her2/neu equivocal (2+) and Her2/neu negative (1+/0) were measurable in 14.2%, 32.9% and 52.9% of the samples, respectively. FISH showed that Her2/neu gene was amplified in 22 cases, 10 Her2/neu positive (3+), 11 (39.3%) Her2/neu equivocal (2+) and 1 Her2/neu negative (1+) cases with IHC staining. There was a higher Her2/neu positivity (3+) in intestinal type and mixed carcinoma, and moderately differentiated tumors. None of the gastritis, intestinal metaplasia or adenoma with low grade dysplasia cases showed positivity for Her2/neu (3+). The Her2/neu positivity (3+) was associated with both adenocarcinoma cases and high grade dysplasia (P = 0.002).